One of Otsuka Pharmaceutical’s U.S. arms has struck a deal with Mindset Pharma, constituting what Bloomberg describes as “a rare endorsement by big pharma of the new and mostly illegal field of drugs.” The collaboration was further explained in a press release, which explained that the McQuade Center for Strategic Research and Development (MSRD) has made an upfront cash payment of $5m to Mindset…


Previous articleCybin Announces Additional Adelia Milestone Achievement
Next articleMydecine Innovations Group Engages JBN Partners, LLC for Marketing Services